At the meeting scheduled for July 12-13, PEAC members will provide recommendations on factors that FDA auditors should consider when evaluating the benefits and risks of AR/VR devices. The panel will also discuss specific challenges that AR/VR presents to vulnerable populations, such as children or those with cognitive disabilities.
The panel will also discuss how patient views can be incorporated into FDA and industry decision-making regarding the benefits and risks of AR/VR technology, as well as factors that healthcare providers should consider when considering AR/VR adoption.
More information about the meeting is available on the FDA’s website.
Copyright © 2022 AuntMinnie.com